Browsing Tag
Zurich
13 posts
What TTM Technologies’ European move reveals about the next PCB supply-chain battleground
Find out how TTM Technologies’ European PCB acquisitions could affect TTMI stock, advanced electronics and medical and defense supply chains today!
Is AXISCADES moving up the aerospace value chain or selling the business that built its credibility?
Read how AXISCADES’ Akkodis deal could fund its Power 930 plan and reshape #AXISCADES into a defence and space manufacturing platform.
Cognite and ABB bring agentic AI into industrial workflows as Aker BP becomes first customer
Cognite and ABB are bringing agentic AI into industrial workflows with Aker BP as first customer. Find out what this means for energy operations.
Amcor (ASX: AMC) climbs as Berry Global synergies exceed targets and Q3 revenue beats consensus
Amcor's Berry Global merger is one year old. Synergies just exceeded targets. The Iran war is forcing higher inventory. The integration thesis is intact.
VERAXA Biotech clears final shareholder hurdle as Voyager Acquisition votes yes on $1.35bn oncology de-SPAC
Voyager Acquisition shareholders approve VERAXA Biotech combination. The cancer ADC and TCE platform heads to NASDAQ as VRXA. Read the full analysis.
The $111.5m deal that could upend London, Zurich and Hong Kong’s dominance in gold trade
Discover how the $111.5 M SMX–DMCC deal could reshape global gold trade and challenge the long-held dominance of London, Zurich, and Hong Kong.
Genfit abandons VS-01 in ACLF after safety scare—can a pivot to UCD rescue GNFT’s pipeline story?
Genfit ends VS-01 in ACLF and refocuses on UCD, trims spend, and extends runway beyond 2028. Find out what it means for GNFT stock and 2025 catalysts.
Houlihan Lokey’s Sandro Galfetti hire: What it means for private equity secondaries
Houlihan Lokey adds Sandro Galfetti to lead its GP-led secondary advisory practice in Europe. Find out how this hire deepens its private capital capabilities.
ABB unveils $2.3bn robotics spin-off plan—shareholders to receive direct stock in 2026 listing
Find out how ABB plans to spin off its robotics division into a $2.3B standalone firm by 2026, offering shareholders a direct stake in automation's future.
NLS Pharmaceutics and Kadimastem merger aims to redefine diabetes treatment with multi-target therapies
NLS Pharmaceutics Ltd., a Swiss clinical-stage biopharmaceutical company specialising in therapies for rare and complex central nervous system…